Proteome Regulatory News (PRM)

1 June 2026

 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Directorate Changes

The directors of Proteome Sciences plc announce that Dr Ian Pike has decided to step down from his executive role as Chief Scientific Officer with effect from 31 May 2026. To maintain continuity, Dr Pike will assume a Non-Executive Director position on the same date, whereby he has committed to provide consultancy services as required to cover his former responsibilities at Proteome Sciences. In this way the business will continue to benefit from Dr Pike's considerable expertise and industry knowledge, whilst allowing him a better time-balance for his personal life.

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: https://www.proteomics.com/

The Company's LEI is 213800Q62ICXANKU2986.